FindTrial
Sign In

A national wide Survey in Doctors to evaluate the Knowledge, Attitude, and Practices (KAP) on combination of three drugs which prevent heart attack.

A national wide CrossSectional Survey to evaluate the Knowledge, Attitude, and Practices (KAP) on Triple Combination Therapy of Rosuvastatin 10/20 mg Plus Aspirin 75 mg Plus Clopidogrel 75 mg) among Health Care professionals in India (KASPER). - KASPER

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/08/044954
Enrollment
150
Registered
2022-08-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Reddys Laboratories Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthcare Professionals specialized in internal medicine and cardiology across geographical locations in India. 2. Minimum 5 years of experience in field of Medicine or Cardiology and with this triple drug combination.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
To assess the knowledge, attitude and practices of Healthcare Professionals on the appropriate placement of triple combination therapy in ACS, right patient profile and its clinical relevance in their practice.Timepoint: One time—

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactPravinkumar Pal

Dr Reddy’s Laboratories Ltd

Rahul.Rathod@drreddys.com04049048400

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026